Xcout Intel
Gate2Brain
Gate2Brain is a biotechnology company dedicated to developing therapeutics that can efficiently cross biological barriers, such as the blood-brain barrier. It was founded as a spin-off from IRB Barcelona, the University of Barcelona, and Hospital Sant Joan de Déu.
Subscribe to see Gate2Brain’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Gate2Brain at a glance
Gate2Brain is a biotechnology company headquartered in Spain. Its most recent funding round raised $7.7M in June 2026. Xcout tracks 2 named people at Gate2Brain, including Dr. Meritxell Teixidó (CEO CSO).
Gate2Brain leadership
- Dr. Meritxell TeixidóCEO CSO
- Meritxell TeixidóCEO
Gate2Brain funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $7.7M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Gate2Brain news
Investors
Gate2Brain competitors
A few of Gate2Brain's closest competitors — see the full list of competitors and alternatives →
Cajal Neuroscience (Cajal Therapeutics Inc.) is a biotechnology company headquartered in Seattle, Washington. The company is dedicated to advancing therapeutic pipelines in neuroscience research.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Dome Therapeutics is a preclinical biotechnology company developing a nanomedicine designed to target brain cancer stem cells that survive standard glioblastoma treatments and drive tumor recurrence. Using a proprietary nanoparticle delivery platform, the company aims to cross the blood-brain barrier to deliver therapeutic payloads directly to these treatment-resistant cells.
BrainZell is a Swedish biotechnology company headquartered in Stockholm that develops human brain cell models and patient-relevant brain organoids. Founded in 2020, the company leverages these advanced biological models for AI-native drug discovery to accelerate the development of life-changing therapies.
Adaptin Bio is a biotechnology company developing a proprietary drug delivery platform designed to enhance the transfer of therapeutics across biological barriers into the brain and other targeted tissues. Its lead technology, the Brain Bispecific T cell Engager (BRiTE) platform, manipulates the human immune system to target diseases in oncology, central nervous system disorders, autoimmune conditions, and cardiovascular markets.
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Get Gate2Brain's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Gate2Brain in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access